Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis

NCT05779007 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05779007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05779007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
April 18, 2023
Completion date
July 14, 2023
Enrollment
2,778 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis